Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 36,202

Document Document Title
WO/2018/069468A1
The present invention relates to compounds of Formula (I), which are DYRK1A and/or DYRK1B inhibitors,and their use in the treatment of neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), metabolic d...  
WO/2018/069892A1
This application relates to various crystalline forms of 4-(2-((1R,2R)-2-hydroxycyclohexylamino)benzothiazol-6-yloxy) -N-methylpicolinamide hydrochloride salts as well as compositions and methods of using the same. In some embodiments th...  
WO/2018/071622A1
The present invention provides compounds of Formula (I) wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.  
WO/2018/069863A1
A compound of formula (I), wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Du...  
WO/2018/068283A1
Provided herein are compounds of formula (I) wherein R 1, Y, L 1, G 1, X 1, X 2, L 2, R 2, R 3, and R 4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, which are useful as agents in the...  
WO/2018/065636A1
This invention relates to β-lactam compounds in combination with further drugs, e.g. β- lactamase inhibitors (BLIs), for use in the treatment and prophylaxis of infections caused by resistant bacteria.  
WO/2018/067615A1
The present invention provides compounds, e.g., compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are i...  
WO/2018/065768A1
The present invention relates to cyano-substituted-heterocycles of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having u...  
WO/2018/059531A1
A crystal form of an adenosine A2A receptor antagonist drug, tozadenant, and a preparation method and use thereof. The prepared tozadenant has crystal form CS1, can be used to prepare an adenosine A2A receptor antagonist drug formulation...  
WO/2018/059314A1
Provided are azabicycle derivatives and a preparation method and use thereof. In particular, provided are an FXR agonist compound and a stereomer, a tautomerid, a polymorphic substance, a solvate (such as a hydrate), a pharmaceutically a...  
WO/2018/060072A1
The invention relates to new substituted benzimidazoles, to methods for the production thereof, to the use thereof alone or in combinations to treat and/or prevent diseases, and to the use thereof to produce drugs for treating and/or pre...  
WO/2018/064589A1
The present application provides bifunctional compounds of Formula I or II: or an enantiomer, diastereomer, or stereoisomer, or a pharmaceutically acceptable salt thereof, which act as protein degradation inducing moieties. The present a...  
WO/2018/060742A1
The present invention relates to a class of substituted-cyanopyrrolidines of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30)...  
WO/2018/064119A1
Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.  
WO/2018/062778A1
The present disclosure relates to an organic electroluminescent device comprising a first electrode, a second electrode facing the first electrode, a light-emitting layer between the first electrode and the second electrode, and an elect...  
WO/2018/064080A1
Compounds disclosed herein including compounds of Formula I: and salts thereof are provided. Pharmaceutical compositions comprising compounds disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for ...  
WO/2018/062978A1
The present invention relates to a novel heteroaryl compound, an enantiomer, a diastereomer or a pharmaceutically acceptable salt thereof, and an antiviral composition comprising the same as an active ingredient. The novel compounds repr...  
WO/2018/060689A1
The present invention relates to substituted-cyanopyrrolidines of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having ut...  
WO/2018/060482A1
The present application relates to new fluorescent dyes and their uses as fluorescent labels. The compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.  
WO/2018/055402A1
The present invention relates to compounds of formula (I), and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity: (Formula (I)) wherein X, R1, R2, and n are each as defined her...  
WO/2018/057808A1
The present application provides the compounds of formula I or IA or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein s, t, m, n, R1, R2, R3, R4, R5, R6 and R7are as described herein. The compounds of f...  
WO/2018/053588A1
The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis.  
WO/2018/055235A1
The present invention concerns compounds of Formula 1a and its uses as a drug, particularly in treatment of cardiac diseases, and in methods and products relating to cell differentiation.  
WO/2018/055526A1
The present invention relates to pyrrolidine sulfonamide analogs (I), pharmaceutical compositions containing them and their use as TRPV4 antagonists.  
WO/2018/055135A1
A method of controlling or preventing infestation of useful plants by phytopathogenic microorganisms, wherein a fungicidally effective amount of a compound of Formula (I) wherein the substituents are as defined in claim 1, is applied to ...  
WO/2018/054989A1
The invention relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing said compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kin...  
WO/2018/055040A1
There are disclosed certain novel compounds (including pharmaceutically acceptable salts thereof) (I) that inhibit phosphatidylinositol 3-kinase gamma (PI3Kδ) and phosphatidylinositol 3-kinase gamma (ΡΙ3Κγ) activity, to their utilit...  
WO/2018/055097A1
The present invention relates to LIM Kinase inhibitors of Formula (I) and pharmaceutically acceptable salts or solvates thereof, wherein R1, R2, R3, R4, X1, X2, X3, Y1, Y2 and Z are as defined in the claims, and their use for the treatme...  
WO/2018/052065A1
Provided is a heterocyclic compound that can have a PRS inhibitory effect and is expected to be of use as a prophylaxis or a therapeutic agent for PRS-related diseases, including cancer. A compound or a salt thereof, said compound being ...  
WO/2018/052772A1
The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these comp...  
WO/2018/051252A2
An object of the present invention is to provide an amide compound or a salt thereof that controls a mite. The present invention provides an amide compound represented by Formula (1) : or a salt thereof, wherein R1 represents C1-6 alkyl ...  
WO/2018/051107A1
There is provided novel small molecule E3 ubiquitin ligase protein binding ligand compounds, and to their utility in PROteolysis Targeted Chimeras (PROTACs), as well as processes for their preparation thereof, and use in medicine. There ...  
WO/2018/050656A2
The present disclosure relates to a class of mammalian heat shock factor (HSF) inhibitors, to pharmaceutical compositions comprising these inhibitors as well as to methods for using the inhibitors. The inhibitors inhibit stress-induced e...  
WO/2018/052066A1
Provided is a heterocyclic compound that can have a PRS inhibitory effect and is expected to be of use as a prophylaxis or a therapeutic agent for PRS-related diseases, including cancer. A compound or a salt thereof, said compound being ...  
WO/2018/052244A1
The present disclosure relates to an organic electroluminescent device. The organic electroluminescent device of the present disclosure comprises a specific combination of an electron buffer material and an electron transport material wh...  
WO/2018/051822A1
Provided is a compound having an adequate coloring peak in a wavelength range (600 nm or more) that does not overlap with the absorption band of blood. Said compound is a 2-substituted benzothiazolyl-3-substituted phenyl-5-substituted su...  
WO/2018/053353A1
The present invention provides compounds according to Formula (I) as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity pr...  
WO/2018/051686A1
The purpose of the present invention is to provide a means that maintains water solubility while making it possible to quantify a biological component with sufficient sensitivity even in the case of a whole blood sample. The present inve...  
WO/2018/053157A1
The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a pat...  
WO/2018/045906A1
Provided is a 2-acylaminothiazole derivative, or a pharmaceutically acceptable salt, ester, solvate, hydrate, isomer, or any crystal form or racemate thereof, or metabolite forms thereof, or mixtures thereof, for therapeutic use in the m...  
WO/2018/045911A1
Provided is a dihydropyrimidine compound of formula (I) or a pharmaceutically acceptable salt or a tautomer or an enantiomer or a diastereomer thereof, wherein R1, R2, R3, R and A are as defined in the description and the claims. Further...  
WO/2018/047983A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, X, Y, Z, D, R1, R2, R3, R4, R12, R15nd R16 are as defined in the specification, a process for their preparation, pharmaceut...  
WO/2018/047948A1
The present invention is capable of providing an organic light-emitting element with a high luminescent efficiency using a compound having a structure which comprises a carbazol-9-yl group substituted with perfluoroalkyl groups at the 2-...  
WO/2018/041091A1
The invention provides a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositi...  
WO/2018/041768A1
The invention relates to novel organic semiconducting (OSC) compounds containing one or more 1,3-dithiolo[5,6-f]benzo-2,1,3-thiadiazole ("DTBTz") or 1,3-dithiolo[6,7-g]quinoxaline ("DTQ") units or derivatives thereof, to methods for thei...  
WO/2018/041563A1
The present invention relates to novel substituted phenoxy- and benzyloxy-piperidine compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes...  
WO/2018/044963A1
The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical composit...  
WO/2018/042343A2
Compounds, specifically protease inhibitors, more specifically 3C and 3CL protease inhibitors, for the treatment of viral infections, and methods of preparing and using such compounds.  
WO/2018/044783A1
Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders...  
WO/2018/041004A1
The present invention relates to an aryl-2,2'-tandem bisthiazole compound and a preparation method and the use thereof. In particular, disclosed in the present invention are an aryl-2,2'-tandem bisthiazole compound with the structure as ...  

Matches 1 - 50 out of 36,202